European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals for felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease.onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Philippines - English - FDA (Food And Drug Administration)

boehringer ingelheim animal health philippines, inc.; distributor: boehringer ingelheim animal health philippines, inc. - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), panleucopenia virus (pli iv) and inactivated calicivirus (fcv 431) and (fcv g1 strains) - suspension for injection (sc) - 1 dose of 1 ml or 0.5 ml contains attenuated feline rhinotracheitis herpesvirus(fhv f2 strain)≥104.9 ccid50; inactivated feline calicivirus (fcv 431 and fcv g1 strains) antigens≥ 2.0 elisa u.; attenuated feline panleucopenia virus (pli iv) ≥103.5 ccid50

United Kingdom - English - VMD (Veterinary Medicines Directorate)

zoetis uk limited - chlamydophila felis, feline calicivirus, feline panleukopenia virus, feline viral rhinotracheitis virus - solution for injection - inactivated viral and bacterial vaccine - cats

United Kingdom - English - VMD (Veterinary Medicines Directorate)

pfizer ltd - feline calicivirus, feline panleukopenia virus, feline viral rhinotracheitis virus -

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

zoetis belgium sa-nv - feline leukemia virus gp70 surface antigen - suspension for injection - feline leukemia virus (felv) - feline leukaemia virus - cat

United Kingdom - English - VMD (Veterinary Medicines Directorate)

boehringer ingelheim vetmedica gmbh - feline calicivirus, feline panleukopenia virus, feline viral rhinotracheitis virus - powder and solvent for suspension for injection - live and inactivated viral vaccine - cats

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

fort dodge australia pty limited - feline calicivirus | feline panleucopenia virus (inactivated) equivalents | feline rhinotracheitis - immunotherapy - cat | kitten | cat - queen | cat - tom | kitten | young cat - not applicable (vet)

United Kingdom - English - VMD (Veterinary Medicines Directorate)

zoetis uk limited - feline leukemia virus - suspension for injection - inactivated viral vaccine - cats

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals for felidae, - cats - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs.onsets of immunity isone week after primary vaccination course.the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease.onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.